Scientific journal
Научное обозрение. Медицинские науки
ISSN 2500-0780
ПИ №ФС77-57452

Personal portfolio

CLINICAL EVALUATION OF ANTI-TUMOR EFFICACY SUBTHERAPEUTIC DOSES OF METOTREXATE, ENDOLYMPHATIC IMPOSED

Rozenko L.Y. 1, Frantsiyants E.M. 1, Dzhabarov F.R. 1
1 Federal State Institution «Rostov Cancer Research Institute» of the Ministry of Health of the Russian Federation
The analysis of a 3 comparable groups of patients with cervical cancer T3NхMo. The control group (29 people) received a standard combined radiotherapy. 37 patients before exposure to regional lymph vessels entered twice at weekly intervals for 25 ± 5 mg methotrexate and 2000 ± 400 mg cyclophosphamide. 29 women endolymphatic introduced only 5 mg of methotrexate. The total effect of controlled regression in the first 2 weeks of treatment was equivalent, respectively – 51,7; 70,3 and 65,5% of cases. Remote 5-year survival with subtherapeutic doses of methotrexate was significantly higher compared with the control 68,4 ± 6,7% vs 48,3 ± 7,1% (p <0,05) and equivalent to 62,8 ± 6,8% in the endolymphatic high doses of cytostatics. Mechanism of anti-tumor effect of subtherapeutic doses of cytostatic agents imposed lymph path, requires further examination.

Библиографическая ссылка

Розенко Л.Я., Франциянц Е.М., Джабаров Ф.Р. КЛИНИЧЕСКАЯ ОЦЕНКА ПРОТИВООПУХОЛЕВОЙ ЭФФЕКТИВНОСТИ СУБТЕРАПЕВТИЧЕЕСКИХ ДОЗ МЕТОТРЕКСАТА, ВВЕДЕНЫХ ЭНДОЛИМФАТИЧЕСКИ // Научное обозрение. Медицинские науки. 2014. № 2. С. 117-118;
URL: https://science-medicine.ru/en/article/view?id=402 (дата обращения: 07.06.2026).